source
- US patients skip half of new high-cost drugs as prices surge past $250KA new report from the Institute for Clinical and Economic Review and West Health finds that only about one-third of patients prescribed newly launched medicines actually fill them within 30 days, w…
- GSK and Ionis receive FDA nod for hepatitis B therapy promising functional cureGSK and Ionis announced that the U.S. Food and Drug Administration has approved their hepatitis B drug bepirovirsen, now marketed as Hibsago. The therapy is intended for chronic hepatitis B patien…